
Paxovir150 mg+100
Eskayef Bangladesh Ltd.
Nirmatrelvir + Ritonavir is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older and more.
Nirmatrelvir + Ritonavir is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older, weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.
| Renal Function | Dose | Duration |
|---|---|---|
| Normal to mild renal impairment (eGFR ≥ 60 mL/min) | Nirmatrelvir 300 mg (two 150 mg tablets) with Ritonavir 100 mg (one tablet), taken together, twice daily | 5 days |
| Moderate renal impairment (eGFR ≥ 30 to < 60 mL/min) | Nirmatrelvir 150 mg (one tablet) with Ritonavir 100 mg (one tablet), taken together, twice daily | 5 days |
| Severe renal impairment (eGFR < 30 mL/min) or severe hepatic impairment | Not recommended (insufficient data) | - |
All tablets in a dose of Nirmatrelvir + Ritonavir should be taken together, by mouth, with or without food, at approximately the same times each day. Treatment should begin as soon as possible after diagnosis and within 5 days of symptom onset, and should be continued for the full 5-day course even if symptoms improve.
Adherence note: Take Nirmatrelvir + Ritonavir exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, as incomplete courses may be associated with reduced effectiveness or symptom/viral rebound.
If a dose is missed within 8 hours of the scheduled time, it should be taken as soon as possible and the regular schedule resumed; if more than 8 hours have passed, the missed dose should be skipped and the next dose taken at its regular time. Doses should not be doubled.
Most reported adverse effects of Nirmatrelvir + Ritonavir are mild to moderate. Commonly reported effects include:
A recurrence of COVID-19 symptoms and/or a new positive test result 2-8 days after completing treatment ("viral/symptom rebound") has been reported in some patients and is generally self-limiting.
Nirmatrelvir + Ritonavir is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.